ANKİLOZAN SPONDİLİTLİ HASTALARDAANTİ-TNF-ALFA TEDAVİ ÖNCESİ VE SONRASI SAKROİLİAK EKLEMLERİN MANYETİK REZONANS İLE GÖRÜNTÜLENMESİ

Year 2013, Volume: 14 Issue: 3, 1 - 5, 01.12.2013

Şenol Kobak Fahrettin Oksel Vedat İnal Yasemin Kabasakal

Abstract

AMAÇ: Çalışmanın amacı, dirençli AS'li hastalarda, anti-TNF-alfa ilaçların etkinliğini ve güvenirliğini yanısıra, manyetik rezonans (MR) görüntüleme ile tedavi öncesi ve sonrası sakroiliak eklem değişiklerini tespit etmektir.GEREÇ ve YÖNTEM: Modifiye New York tanı kriterlerine göre AS tanısı almış, 27 hasta çalışmaya dahil edildi. Sakroiilitis bulguları, anti-TNF-alfa tedavi öncesi ve sonrası, Gd-MR ile tespit edildi. Sekiz hastaya, 4 haftada bir İnfliximab 4mg/kg i.v. infüzyon verildi. Diğer 19 hastaya ise Etanercept 2x25mg/hafta s.c. verildi. Değerlendirilen klinik ve laboratuvar parametreler; BASDAİ, BASFİ, ağrı (VAS skoru), Schöber testi, göğüs ekspansiyonu, C-reaktif protein (CRP), eritrosit sedimentasyon hızı (ESH).BULGULAR: Hastaların çoğu, anti-TNF-alfa tedavilerine iyi yanıt verdi. 24.haftanın sonunda, takip edilen tüm parametrelerde iyileşme gözlendi. MR görüntüleme çalışmalarında, anti-TNF-alfa tedavi sonrası sadece 3 hastanın sakroiliak eklem inflamasyonunda gerileme gözlendi. SONUÇ: Aktif AS'li hastalarda, 24.hafta sonunda anti-TNF-alfa ilaçları güvenilir ve etkin bulundu. BASDAİ, BASFİ, ağrı skorlarında belirgin düşüş gözlendi. Fakat, sakroiliak eklemin akut inflamatuvar bulgularında, MR görüntüleme ile herhangi bir gerileme tespit edilmedi

Keywords

Ankilozan spondilit, anti-TNF-α ilaçlar, manyetik rezonans görüntüleme, sakroiliak eklem

Magnetic Resonance Imaging of the Sacroiliac Joints in Ankylosing Spondylitis Before and After Therapy with Anti-Tumor Necrosis Factor Alpha

Abstract

OBJECTIVE: The goal of this study is to assess the changes in the sacroiliac joints (Sİ) by magnetic resonance imaging (MRI) in a 24-week follow-up period and to determine the efficacy and safety of anti-TNF-α therapies for refractory AS. MATERIAL and METHODS: Twenty-seven patients who met the modified New York criteria for AS were enrolled in this study. Activity of sacroiliitis was determined by Gd-MRI scan before and after anti-TNF-α treatment. Eight patients received infliximab at a dose of 4 mg/kg by intravenous infusion over 2 hours at every 4 week. Other 19 patients were treated with 25mg subcutaneous etanercept twice weekly The total observational period was 24 weeks. The clinical and laboratory variables included: Bath AS Disease Activity Index (BASDAI), Bath AS Functional Index (BASFI), pain on a visual analog scale, Schober's index, chest expansion, C-reactive protein (CRP), erythrocyte sedimentation rate (ESR). RESULTS: Most patients responded well to treatment of anti-TNF-α antagonists. At 24 weeks, there was an improvement in all of the following measures. Imaging studies showed decreased inflammation of the SI joints after 24 weeks of treatment with anti-TNF-α therapies in only 3 patients. CONCLUSION: The anti-TNF-α therapies was safe and effective in treating patients with active AS during 24- week study period. The BASDAI, BASFI, VAS of pain were decreased well. But we could not determine any regression of acute inflammatory changes of the SI joints as depicted by MRI.

Keywords

Ankylosing spondylitis, anti-TNF-α therapies, magnetic resonance imaging, sacroiliac joints

References

• 1. Khan MA. Update on spondyloarthropaties. Ann Intern Med 2002;136:896-907.
• 2. S i e p e r J , B r a u n J . P a t h o g e n e s i s o f spondylarthropathies: persistan bacterial antigen, autoimmunity, or both? Arthritis Rheum 1995;38:1547-54.
• 3. Braun J, Sieper J.The sacroiliac joint in the spondylarthropathies. Curr Opin Rheumatol 1996;7:275-83.
• 4. Braun J, Bollow M, Sieper J. Radiologic diagnosis and pathology of the spondylarthropathies. Rheum Dis Clin North Am 1998;24:697-735.
• 5. Dougados M, vam der Linden S, Leirisalo-Repo M, Huitfeldt B, Juhlin R, Veys E, Zeidler H, Kvien TK, Olivieri I, Dijkmans B, et al. Sulfasalazine in the treatment of spondyloarthropathy: A randomized, multicentre, double-blind, placebo-controlled study. Arthritis Rheum 1995;38:618-27.
• 6. Clegg DO, Reda DJ, Weisman MH, Blackburn WD, Cush JJ, Cannon GW, Mahowald ML, Schumacher HR Jr, Taylor T, Budiman-Mak E, Cohen MR, Vasey FB, Luggen ME, Mejias E, Silverman SL, Makkena R, Alepa FP, Buxbaum J, Haakenson CM, Ward RH, Manaster BJ, Anderson RJ, Ward JR, Henderson WG. Comparison of sulphasalazine and placebo in the treatment of ankylosing spondylitis. Arthritis Rheum 1996;39:2004-12.
• 7. Braun J, Bollow M, Neure L, Seipelt E, Seyrekbasan F, Herbst H, Eggens U, Distler A, Sieper J. Use of immunohistologic and in situ hybridization techniques in the examination of sacroiliac joint biopsy specimens from patients with ankylosing spondylitis. Arthritis Rheum 1995;38:499-505.
• 8. Van den Bosch F, Kruithof E, Baeten D, De Keyser F, Mielants H, Veys EM. Effects of loading dose regiment of three infusions of chimeric monoclonal antibody to tumor ne c rosis f a c tor α (infliximab) in spondyloarthropathy: an open pilot study. Ann Rheum Dis 2000;59:428-33.
• 9. Brandt J, Haibel H, Cornely D, Golder W, Gonzalez J, Reddig J, Thriene W, Sieper J, Braun J. Successful treatment of active ankylosing spondylitis with the anti-tumor necrosis factor α monoclonal antibody infliximab. Arthritis Rheum 2000;43:1346-52.
• 10. Brandt J, Khariouzov A, Listing J, Haibel H, Sorensen H, Grassnickel L, et al. Six-month results of a doubleblind, placebo-controlled trial of etanercept treatment in patients with active ankylosing spondylitis. Arthritis Rheum 2003;48:1667–75.
• 11. Oostveen JC, van de Laar MA. Magnetic resonance imaging in rheumatic disorders of the spine and SI joints. Semin Arthritis Rheum 2000;30:52-69.
• 12. Bollow M, Brandt J, Haberle HJ, Sieper S, Hamm B. Use of magnetic resonance imaging to detect spinal i n f l a m m a t i o n i n s p o n d y l o a r t h r o p a t h y patients(abstract). Arthritis Rheum 1998;41Suppl 9:S358.
• 13. Braun J, Bollow M, Eggens U, König H, Distler A, Sieper J. Use of dynamic magnetic resonance imaging with fast imaging in the detection of early and advanced sacroiliitis in spondyloarthropathy patients. Arthritis Rheum 1994;37:1039-45.
• 14. Rudwaleit M, Baraliakos X, Listing J, Brandt J, Sieper J, Braun J. Magnetic resonance imaging of the spine and the sacroiliac joints in ankylosing spondylitis and undifferentiated spondyloarthritis during treatment with etanercept Ann Rheum Dis 2005;64;1305-1310
• 15. Braun J, Baraliakos X, Golder W, Brandt J, Rudwaleit M, Listing J, Bollow M, Sieper J, van der Heijde D. Magnetic resonance imaging examinations of the spine in patients with ankylosing spondylitis, before and after successful therapy with infliximab. Arthritis & Rheumatism Vol. 48, No. 4, April 2003, pp 1126–1136.
• 16. Jee WH, McCauley TR, Lee SH, Kima SH, Ima SA, Had KY. Sacroiliitis in patients with ankylosing spondylitis: association of MR findings with disease a c t i v i t y. M a g n e t i c r e s o n a n c e i m a g i n g 2004:22;245–250.
• 17. Bollow M, Fischer T, Reisshauer H, Backhaus M, Sieper J, Hamm B, et al. Quantitative analyses of sacroiliac biopsies in spondylarthropathies: T cells and macrophages predominate in early and active sacroiliitis—cellularity correlates with the degree of enhancement detected by magnetic resonance imaging. Ann Rheum Dis 2000;59:135–40.
• 18. Bollow M, Enzweiler C, Taupitz, Golder W, Hamm B, Sieper J, et al. Use of contrast enhanced magnetic resonance imaging to detect spinal inflammation in patients with spondyloarthritides. Clin Exp Rheumatol 2002;20 Suppl 28:167-74.